Overview

Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency

Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this phase II trial is to determine the efficacy and safety of testosterone replacement therapy (TRT) in improving the symptoms of androgen deficiency and health-related quality of life in men with prostate cancer who have undergone radical prostatectomy.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Shalendar Bhasin, MD
Collaborator:
National Institute on Aging (NIA)
Treatments:
Androgens
Methyltestosterone
Testosterone
Testosterone 17 beta-cypionate
Testosterone enanthate
Testosterone undecanoate